For citation purposes: Deodato F, Macchia G, Cilla S, Pomo A, Caravatta L, Cellini F, Ciabattoni A, Mattiucci GC, Buwenge M, Valentini V, Piermattei A, Morganti AG. Stereotactic radiotherapy of pancreatic cancer: techniques and results. OA Minimally Invasive Surgery 2013 Oct 26;1(1):4.

Review

 
Hepatobiliary

Stereotactic radiotherapy of pancreatic cancer: techniques and results

F Deodato, G Macchia, S Cilla, A Pomo, L Caravatta, F Cellini, A Ciabattoni, GC Mattiucci, M Buwenge, V Valentini, A Piermattei, AG Morganti,,
 

Authors affiliations

(1) Department of Radiation Oncology, Fondazione Giovanni Paolo II, Campobasso, Italy

(2) Department of Medical Phisics, Fondazione Giovanni Paolo II, Campobasso, Italy

(3) Department of Radiation Oncology, Ospedale San Francesco, Nuoro, Italy

(4) Department of Radiation Oncology, Campus Biomedico University, Roma, Italy

(5) Department of Radiation Oncology, Ospedale San Filippo Neri, Roma, Italy

(6) Department of Radiation Oncology, Università Cattolica del Sacro Cuore, Roma, Italy

(7) Department of Medical Phisics, Università Cattolica del Sacro Cuore, Roma, Italy

(8) Department of General Oncology, Fondazione Giovanni Paolo II, Campobasso, Italy

* Corresponding author Email: gmacchia@rm.unicatt.it

Abstract

Introduction

Stereotactic body radiotherapy in the treatment of pancreatic carcinoma is a recent technique. The aim of this analysis is to present a summary of techniques and clinical results.

Material and Methods

Stereotactic body radiotherapy allows to perform a local treatment of the tumour in shortened time (1–5 days) compared with traditional treatments (about 1 month) but requires complex planning and delivery techniques with specific accessories for image-guided radiotherapy. The studies published to date are characterised by small series and very different methods in terms of dose, fractionation, techniques and evaluation modalities.

Results

The preliminary published results are positive in terms of tumour response (ORR: 50%) and local control of the tumour (crude rate: 80%). However, gastrointestinal toxicity seems to be the main limitation of stereotactic body radiotherapy, especially at the duodenal level.

Conclusion

If stereotactic body radiotherapy of pancreatic carcinoma will be standardised and optimised, reducing the risk of bowel toxicity, in the future it may have an increasing role in the field of integrated treatments of this tumour.

Licensee OA Publishing London 2013. Creative Commons Attribution License (CC-BY)